Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Opioid-Induced Constipation Treatment Market Forecast: What Market Value Is Expected By 2030?
The market catering to treatments for opioid-induced constipation has experienced robust expansion recently. Projections indicate a rise from $1.9 billion in 2025 to $2.02 billion in 2026, reflecting a compound annual growth rate of 6.7%. This past expansion was fueled by several key factors: the extensive prescription of opioids for managing persistent pain, the insufficient efficacy of conventional laxative treatments, an increasing incidence of pain associated with cancer, a deficiency in therapies specifically designed for opioid-induced constipation early on, and a greater number of hospital admissions arising from adverse opioid reactions.
The market for treatments addressing opioid-induced constipation is projected for significant expansion over the forthcoming years, anticipating a valuation of $2.54 billion by 2030, fueled by a compound annual growth rate of 5.9%. This projected expansion stems from several key drivers: escalating demand for therapies centered on PAMORA, a consistent increase in long-term opioid prescriptions, particularly within an aging demographic, a heightened clinical emphasis on pain management approaches that prioritize the patient’s experience, enhanced accessibility through both online and traditional retail pharmacies, and augmented investments in the development of drugs for gastrointestinal conditions. Significant trends expected to shape this market during the forecast period involve a greater uptake of peripherally acting µ-opioid receptor antagonists, a growing inclination towards OIC therapies that specifically target the condition without compromising pain relief, an increased integration of both medicinal and non-medicinal treatment strategies, a stronger emphasis on enhancing the quality of life for individuals managing chronic pain, and a rising level of awareness alongside improved diagnosis rates for opioid-induced constipation.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp
Opioid-Induced Constipation Treatment Market Demand Drivers: What Is Fueling Industry Growth?
The increasing utilization of opioids for managing both cancer-related and non-cancer pain is anticipated to be a significant driver for the opioid-induced constipation treatment market’s expansion. Cancer pain stems from the disease itself or its therapeutic interventions, whereas non-cancer pain originates from conditions independent of malignancy. The prescription of opioids for these pain conditions is predominantly motivated by the necessity for effective management of moderate to severe pain, taking into account pain severity, duration, individual patient responses to alternative therapies, and the overarching therapeutic objective of enhancing life quality while diligently mitigating addiction risks and adverse effects. Treatments designed for opioid-induced constipation (OIC) offer relief to patients experiencing discomfort from opioid use, regardless of whether their pain is cancer-related or not. By alleviating this specific side effect, OIC treatments contribute to greater patient comfort, improved compliance with prescribed pain management plans, and an overall better quality of life without sacrificing the efficacy of pain relief. Illustrating this trend, the Centers for Disease Control and Prevention, a prominent US health authority, reported in November 2024 that in 2023, approximately 37.5 opioid prescriptions were dispensed for every 100 individuals. High dispensing rates were observed in states such as Arkansas with 71.5, Alabama with 71.4, Mississippi with 63.1, and Louisiana with 62.7 prescriptions per 100 individuals in 2023. Consequently, the elevated use of opioids for managing cancer and non-cancer pain directly fuels the growth trajectory of the market dedicated to treating opioid-induced constipation.
Opioid-Induced Constipation Treatment Market Categorization By Product Type And Application
The opioid-induced constipation treatment market covered in this report is segmented –
1) By Drug Class: Laxatives, Peripherally Acting µ-opioid Receptor Antagonists, Serotonin Receptor Agonists
2) By Type: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives
2) By Peripherally Acting µ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan
3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod
Opioid-Induced Constipation Treatment Market Innovation Trends: Which Developments Are Transforming The Industry?
Within the market for treatments targeting opioid-induced constipation, prominent pharmaceutical entities are actively engaged in pioneering novel therapeutic approaches. Their efforts are particularly concentrated on the development of innovations like peripherally acting µ-opioid receptor antagonists (PAMORAs). These agents are designed for precise modulation of receptors within the gastrointestinal tract, aiming to elevate treatment effectiveness, foster greater patient adherence, and mitigate undesirable systemic reactions that can occur during opioid-based pain management. A key characteristic of PAMORAs is their ability to selectively impede µ-opioid receptors exclusively in the digestive system, without permeating the blood-brain barrier. This targeted action facilitates the restoration of normal bowel movements while preserving the pain-relieving effects provided by central pain management strategies, distinguishing them from conventional laxatives which fail to address the root cause of constipation stemming from receptor activity. Illustrating this advancement, in May 2025, Luye Pharma, a pharmaceutical firm headquartered in China, introduced Mimeixin, a formulation combining oral oxycodone and naloxone in a sustained-release tablet format, specifically engineered for OIC management. This once-daily treatment not only provides pain relief but also counteracts opioid activity in the gut, offering enhanced bowel regularity and a reduction in gastrointestinal adverse effects when contrasted with earlier treatment options. Consequently, Mimeixin presents a convenient solution for patients, integrating pain alleviation and constipation control into a single, easy-to-take medication.
Opioid-Induced Constipation Treatment Market Company Landscape And Strategic Competition
Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Cumberland Pharmaceuticals Inc., RedHill Biopharma Ltd., Theravance Biopharma Inc., Mundipharma International Limited, Daiichi Sankyo Co Ltd, Progenics Pharmaceuticals Inc, Shionogi & Co Ltd, Purdue Pharma, Nektar Therapeutics, S L A Pharma AG, Bristol-Myers Squibb Company, Fresenius Kabi AG, Viatris Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, F Hoffmann-La Roche Ltd, Aurobindo Pharma, Abbott Laboratories, Daewoong Pharmaceutical Company
Access The Complete Opioid-Induced Constipation Treatment Market Report:
Opioid-Induced Constipation Treatment Market Regional Distribution: Which Areas Drive Market Expansion?
North Americawas the largest region in the opioid-induced constipation treatment market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model